Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy

Lilly’s Omvoh shows rare long-term remission milestone in ulcerative colitis

OneSource powers second generic semaglutide nod in Canada

Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs

NIFTY Pharma remains resilient amid mixed market sentiment

Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures

Zealand Pharma and Roche charge into Phase 3 with obesity drug bet

The Danish biotech company confirmed the global study will begin in the second half of 2026

OneSource Pharma, Dr Reddy’s secure Health Canada nod for generic Semaglutide

Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility

AbbVie seeks FDA nod for subcutaneous SKYRIZI induction in Crohn’s disease

The submission is backed by positive results from the Phase 3 AFFIRM study

AstraZeneca wins US nod for at-home lupus treatment in major shift for SLE care

The approval was driven by data from the Phase III TULIP-SC trial

Biocon receives Health Canada approval for Bosaya and Vevzuo biosimilars to Prolia and Xgeva

Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions

Orbicular's partner secures tentative U.S. ANDA approval for a generic version of Ozempic

OneSource is the contract development and manufacturing organization (CDMO) partner for this product